KLRA
Kailera Therapeutics, Inc.
Price Chart
Latest Quote
$20.66
-0.71 (-3.32%)
Current Price
| Previous Close | $21.37 |
| Open | $21.37 |
| Day High | $21.37 |
| Day Low | $20.20 |
| Volume | 366,142 |
Stock Information
| Shares Outstanding | 129.57M |
| Net Income | $-148.96M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.68B |
| EPS (TTM) | $-1.78 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Income | $-148.96M |
| Book/sh | $-18713.67 |
| Employees | 145 |
Financial Ratios
| Quick Ratio | 11.83 |
| Current Ratio | 12.02 |
Returns & Margins
| ROA | -22.73% |
| ROE | -36.90% |
Ownership
| Institutional Ownership | 43.12% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.54 |
| P/B | -0.00 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $42.60 |
Technical Indicators
| SMA20 | $20.74 |
| RSI | 48.63 |
| ATR | 1.6411 |
| Shares Float | 9K |
| Short Float | 2.07% |
| Short Ratio | 5.96 |
| Rel Volume | 0.60 |
Performance History
| Week | +8.00% |
| Month | -4.22% |
| YTD | -20.54% |
| 10 Years | -20.54% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $20.66 | 417,473 |
| 2026-06-24 | $21.37 | 474,000 |
| 2026-06-23 | $21.37 | 531,400 |
| 2026-06-22 | $22.88 | 715,900 |
| 2026-06-18 | $19.90 | 4,355,800 |
| 2026-06-17 | $19.13 | 746,900 |
| 2026-06-16 | $18.55 | 723,300 |
| 2026-06-15 | $19.67 | 404,000 |
| 2026-06-12 | $18.89 | 411,600 |
| 2026-06-11 | $19.54 | 376,900 |
| 2026-06-10 | $19.14 | 368,600 |
| 2026-06-09 | $19.64 | 577,000 |
| 2026-06-08 | $19.70 | 722,600 |
| 2026-06-05 | $19.37 | 450,700 |
| 2026-06-04 | $20.99 | 489,800 |
| 2026-06-03 | $22.38 | 422,300 |
| 2026-06-02 | $22.59 | 443,600 |
| 2026-06-01 | $23.18 | 299,200 |
| 2026-05-29 | $22.94 | 555,900 |
| 2026-05-28 | $22.94 | 397,100 |
| 2026-05-27 | $21.91 | 479,400 |
| 2026-05-26 | $21.57 | 484,800 |
About Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
đ° Latest News
Kardigan rises in Nasdaq debut after upsized $400 million IPO
Reuters âĸ 2026-06-18T16:56:35Z
3 Under-the-Radar Stocks to Buy and Hold for a Decade
Motley Fool âĸ 2026-06-16T07:50:00Z
âI worry deeply about bioterrorismâ: Is Europe sufficiently prepared for another pandemic?
Euronews âĸ 2026-06-15T04:48:57Z
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?
Motley Fool âĸ 2026-06-12T06:50:00Z
How to Play PBLS Stock After the Parabilis IPO
Barchart âĸ 2026-06-11T19:12:36Z
Parabilis sets a record with a $670M biotech IPO
BioPharma Dive âĸ 2026-06-10T11:06:00Z
This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst
Benzinga âĸ 2026-05-13T18:43:40Z
Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity
Investor's Business Daily âĸ 2026-05-12T20:26:49Z
Kailera IPO And Governance Overhaul Set Terms For NASDAQ Composite Debut
Simply Wall St. âĸ 2026-05-01T23:10:58Z
Kailera Therapeutics indicated to open at $24, IPO priced at $16
TipRanks âĸ 2026-04-17T22:40:16Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 |
|---|---|
| Revenue | |
| Total Revenue | $0 |
| Operating Revenue | $0 |
| Expenses | |
| Total Expenses | $158,340,000 |
| Other Income Expense | $-1,663,000 |
| Other Non Operating Income Expenses | $-1,663,000 |
| Net Non Operating Interest Income Expense | $11,048,000 |
| Operating Expense | $158,340,000 |
| General And Administrative Expense | $49,227,000 |
| Income & Earnings | |
| Net Income From Continuing Operation Net Minority Interest | $-148,955,000 |
| Net Interest Income | $11,048,000 |
| Interest Income | $11,048,000 |
| Normalized Income | $-148,955,000 |
| Net Income From Continuing And Discontinued Operation | $-148,955,000 |
| Total Operating Income As Reported | $-158,340,000 |
| Net Income Common Stockholders | $-148,955,000 |
| Net Income | $-148,955,000 |
| Net Income Including Noncontrolling Interests | $-148,955,000 |
| Net Income Continuous Operations | $-148,955,000 |
| Pretax Income | $-148,955,000 |
| Special Income Charges | $0 |
| Interest Income Non Operating | $11,048,000 |
| Operating Income | $-158,340,000 |
| Per Share | |
| Diluted EPS | $-1.26 |
| Basic EPS | $-1.26 |
| Other | |
| Tax Effect Of Unusual Items | $0 |
| Tax Rate For Calcs | $0 |
| Normalized EBITDA (Bullshit earnings) | $-158,030,000 |
| Total Unusual Items | $0 |
| Total Unusual Items Excluding Goodwill | $0 |
| Reconciled Depreciation | $310,000 |
| EBITDA (Bullshit earnings) | $-158,030,000 |
| EBIT | $-158,340,000 |
| Diluted Average Shares | $117,948,773 |
| Basic Average Shares | $117,948,773 |
| Diluted NI Availto Com Stockholders | $-148,955,000 |
| Gain On Sale Of Business | $0 |
| Research And Development | $109,113,000 |
| Selling General And Administration | $49,227,000 |
| Other Gand A | $49,227,000 |
Fetched: 2026-06-25
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-356,458,000 | $-218,772,000 |
| Total Assets | $692,294,000 | $178,445,000 |
| Total Non Current Assets | $134,757,000 | $834,000 |
| Other Non Current Assets | $3,482,000 | $154,000 |
| Non Current Prepaid Assets | $12,185,000 | $0 |
| Investmentin Financial Assets | $106,672,000 | $0 |
| Current Assets | $557,537,000 | $177,611,000 |
| Other Current Assets | $1,234,000 | $343,000 |
| Prepaid Assets | $7,522,000 | $2,090,000 |
| Receivables | $2,725,000 | $0 |
| Accrued Interest Receivable | $2,725,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $546,056,000 | $175,178,000 |
| Cash And Cash Equivalents | $160,267,000 | $175,178,000 |
| Debt | ||
| Total Debt | $10,753,000 | $509,000 |
| Long Term Debt And Capital Lease Obligation | $9,713,000 | $0 |
| Current Debt And Capital Lease Obligation | $1,040,000 | $509,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $1,048,752,000 | $397,217,000 |
| Total Non Current Liabilities Net Minority Interest | $1,002,347,000 | $390,306,000 |
| Other Non Current Liabilities | $270,000 | - |
| Current Liabilities | $46,405,000 | $6,911,000 |
| Other Current Liabilities | $916,000 | $2,160,000 |
| Payables And Accrued Expenses | $35,395,000 | $2,420,000 |
| Payables | $7,529,000 | $2,008,000 |
| Accounts Payable | $7,529,000 | $2,008,000 |
| Equity | ||
| Common Stock Equity | $-356,458,000 | $-218,772,000 |
| Total Equity Gross Minority Interest | $-356,458,000 | $-218,772,000 |
| Stockholders Equity | $-356,458,000 | $-218,772,000 |
| Gains Losses Not Affecting Retained Earnings | $229,000 | $0 |
| Other Equity Adjustments | $229,000 | - |
| Retained Earnings | $-368,668,000 | $-219,713,000 |
| Preferred Securities Outside Stock Equity | $992,364,000 | $390,306,000 |
| Other | ||
| Ordinary Shares Number | $117,948,773 | $117,948,773 |
| Share Issued | $117,948,773 | $117,948,773 |
| Tangible Book Value | $-356,458,000 | $-218,772,000 |
| Invested Capital | $-356,458,000 | $-218,772,000 |
| Working Capital | $511,132,000 | $170,700,000 |
| Capital Lease Obligations | $10,753,000 | $509,000 |
| Total Capitalization | $-356,458,000 | $-218,772,000 |
| Additional Paid In Capital | $11,981,000 | $941,000 |
| Capital Stock | $0 | $0 |
| Common Stock | $0 | $0 |
| Long Term Capital Lease Obligation | $9,713,000 | $0 |
| Current Capital Lease Obligation | $1,040,000 | $509,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $9,054,000 | $1,822,000 |
| Current Accrued Expenses | $27,866,000 | $412,000 |
| Investments And Advances | $106,672,000 | $0 |
| Available For Sale Securities | $106,672,000 | - |
| Net PPE | $12,418,000 | $680,000 |
| Accumulated Depreciation | $-100,000 | $-53,000 |
| Gross PPE | $12,518,000 | $733,000 |
| Leases | $562,000 | $0 |
| Other Properties | $10,463,000 | $471,000 |
| Machinery Furniture Equipment | $1,493,000 | $262,000 |
| Properties | $0 | $0 |
| Other Short Term Investments | $385,789,000 | $0 |
Fetched: 2026-06-25
Cash Flow Statement (Annual)
| Metric | 2025-12-31 |
|---|---|
| Free Cash Flow | |
| Free Cash Flow | $-122,298,000 |
| Operating Activities | |
| Operating Cash Flow | $-120,210,000 |
| Cash Flow From Continuing Operating Activities | $-120,210,000 |
| Investing Activities | |
| Capital Expenditure | $-2,088,000 |
| Investing Cash Flow | $-492,599,000 |
| Cash Flow From Continuing Investing Activities | $-492,599,000 |
| Financing Activities | |
| Issuance Of Capital Stock | $498,874,000 |
| Financing Cash Flow | $598,659,000 |
| Cash Flow From Continuing Financing Activities | $598,659,000 |
| Net Other Financing Charges | $-315,000 |
| Net Preferred Stock Issuance | $498,874,000 |
| Preferred Stock Issuance | $498,874,000 |
| Net Common Stock Issuance | $498,874,000 |
| Common Stock Issuance | $498,874,000 |
| Other | |
| Issuance Of Debt | $100,000,000 |
| End Cash Position | $161,028,000 |
| Beginning Cash Position | $175,178,000 |
| Changes In Cash | $-14,150,000 |
| Proceeds From Stock Option Exercised | $100,000 |
| Net Issuance Payments Of Debt | $100,000,000 |
| Net Short Term Debt Issuance | $100,000,000 |
| Short Term Debt Issuance | $100,000,000 |
| Net Long Term Debt Issuance | $100,000,000 |
| Long Term Debt Issuance | $100,000,000 |
| Net Investment Purchase And Sale | $-490,511,000 |
| Sale Of Investment | $141,647,000 |
| Purchase Of Investment | $-632,158,000 |
| Net PPE Purchase And Sale | $-2,088,000 |
| Purchase Of PPE | $-2,088,000 |
| Change In Working Capital | $16,781,000 |
| Change In Other Current Liabilities | $-130,000 |
| Change In Other Current Assets | $-143,000 |
| Change In Payables And Accrued Expense | $37,990,000 |
| Change In Accrued Expense | $33,300,000 |
| Change In Payable | $4,690,000 |
| Change In Account Payable | $4,690,000 |
| Change In Prepaid Assets | $-20,936,000 |
| Other Non Cash Items | $660,000 |
| Stock Based Compensation | $10,940,000 |
| Unrealized Gain Loss On Investment Securities | $1,784,000 |
| Amortization Of Securities | $-1,730,000 |
| Depreciation Amortization Depletion | $310,000 |
| Depreciation And Amortization | $310,000 |
| Net Income From Continuing Operations | $-148,955,000 |
Fetched: 2026-06-25